Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

0.87USD
16 Aug 2019
Change (% chg)

$0.07 (+9.19%)
Prev Close
$0.80
Open
$0.80
Day's High
$0.95
Day's Low
$0.77
Volume
428,702
Avg. Vol
206,286
52-wk High
$16.30
52-wk Low
$0.74

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics Reports Qtrly Loss Per Share $1.21
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS, PROVIDES BUSINESS STRATEGY UPDATE AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.ACLARIS THERAPEUTICS - AS OF JUNE 30, 2019, CO HAD AGGREGATE CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $115.5 MILLION VERSUS $168.0 MILLION AS OF DEC 31, 2018.QTRLY NET REVENUES INCREASED TO $5.9 MILLION VERSUS $3.7 MILLION.QTRLY REITERATES THAT IT EXPECTS 2019 GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $61 TO $64 MILLION.QTRLY LOSS PER SHARE $1.21.Q2 EARNINGS PER SHARE VIEW $-0.76, REVENUE VIEW $5.5 MILLION -- REFINITIV IBES DATA.  Full Article

Aclaris Therapeutics Says Phase 2 Trial Of ATI-502 Topical Did Not Meet Endpoints
Thursday, 27 Jun 2019 

June 26 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES PHASE 2 CLINICAL TRIAL OF ATI-502 TOPICAL IN PATIENTS WITH ALOPECIA AREATA DID NOT MEET ENDPOINTS.ACLARIS THERAPEUTICS INC - ATI-502 WAS OBSERVED TO BE GENERALLY WELL-TOLERATED.ACLARIS THERAPEUTICS INC - ATI-502 DID NOT ACHIEVE STATISTICAL SUPERIORITY AT PRIMARY OR SECONDARY ENDPOINTS.ACLARIS THERAPEUTICS INC - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED.ACLARIS THERAPEUTICS - ATI-502 DID NOT ACHIEVE PRIMARY OR SECONDARY ENDPOINTS DUE TO HIGH RATES OF DISEASE RESOLUTION IN VEHICLE-TREATED PATIENTS..  Full Article

FDA Sends Letter To Aclaris Therapeutics Regarding Co's Eskata (Hydrogen Peroxide) Topical Solution
Thursday, 20 Jun 2019 

June 20 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - SENDS LETTER TO ACLARIS THERAPEUTICS REGARDING CO'S ESKATA (HYDROGEN PEROXIDE) TOPICAL SOLUTION (ESKATA).U.S. FDA - OFFICE OF PRESCRIPTION DRUG PROMOTION REVIEWED DIRECT-TO-CONSUMER VIDEO OF INTERVIEW FEATURING PAID ACLARIS SPOKESPERSON REGARDING ESKATA.U.S. FDA - VIDEO OF INTERVIEW FEATURING PAID ACLARIS SPOKESPERSON REGARDING ESKATA WAS ORIGINALLY BROADCAST ON ABC’S THE VIEW ON SEPT. 19, 2018.U.S. FDA - SEPT. 19, 2018 ACLARIS VIDEO MAKES "FALSE OR MISLEADING CLAIMS" &/OR REPRESENTATIONS ABOUT RISKS ASSOCIATED WITH AND EFFICACY OF ESKATA.U.S. FDA - SEPT. 19, 2018 ACLARIS VIDEO FAILS TO INCLUDE INFORMATION ON SERIOUS RISKS FOR ESKATA SUCH AS SERIOUS EYE DISORDERS, SEVERE SKIN REACTIONS.U.S. FDA - CLAIMS IN SEPT. 19, 2018 ACLARIS VIDEO ON ESKATA’S COMMON ADVERSE REACTIONS CREATE MISLEADING IMPRESSIONS OF ITS TREATMENT, SAFETY PROFILE.U.S. FDA - REQUESTS ACLARIS THERAPEUTICS TO SUBMIT WRITTEN RESPONSE TO FDA ON OR BEFORE JUNE 28 REGARDING FDA'S CONCERNS ABOUT ESKATA.  Full Article

Aclaris Therapeutics QTRLY Loss Per Share $0.99
Monday, 18 Mar 2019 

March 18 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q4 REVENUE $3.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.5 MILLION.INITIATES FINANCIAL GUIDANCE FOR FULL YEAR 2019.EXPECTS 2019 GAAP RESEARCH AND DEVELOPMENT (RESEARCH AND DEVELOPMENT) EXPENSES TO BE IN RANGE OF $61 TO $64 MILLION.EXPECTS 2019 GAAP SALES AND MARKETING (S&M) EXPENSES TO BE IN RANGE OF $37 TO $40 MILLION.EXPECTS 2019 GAAP GENERAL AND ADMINISTRATIVE (G&A) EXPENSES TO BE IN RANGE OF $29 TO $31 MILLION.QTRLY LOSS PER SHARE $0.99.  Full Article

Aclaris Therapeutics Q3 Loss Per Share $1.06
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q3 LOSS PER SHARE $1.06.Q3 EARNINGS PER SHARE VIEW $-1.33 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $1.6 MILLION VERSUS I/B/E/S VIEW $1.8 MILLION.UPDATED ITS EXPECTED FY 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $62 MILLION TO $64 MILLION.UPDATED EXPECTED FY 2018 GAAP SELLING, GENERAL AND ADMINISTRATIVE EXPENSES TO BE IN RANGE OF $77 MILLION TO $79 MILLION.  Full Article

Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution
Friday, 6 Apr 2018 

April 6 (Reuters) - Cipher Pharmaceuticals::CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS THERAPEUTICS.CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN UPFRONT PAYMENT OF US$1.0 MLN .  Full Article

Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met
Monday, 19 Mar 2018 

March 19 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS.ACLARIS THERAPEUTICS INC - PRIMARY, SECONDARY, AND EXPLORATORY ENDPOINTS OF PHASE 2 TRIAL MET DURING 8-WEEK TREATMENT PERIOD.ACLARIS THERAPEUTICS - AFTER TREATMENT COMPLETED, GREATER IMPROVEMENT VERSUS. PLACEBO OBSERVED IN 3-MONTH POST-TREATMENT FOLLOW-UP EVALUATION IN TRIAL.ACLARIS THERAPEUTICS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AMONG SUBJECTS TREATED WITH A-101 45%.ACLARIS THERAPEUTICS INC - A-101 45% WAS GENERALLY WELL TOLERATED THROUGH VISIT 13.  Full Article

Aclaris Therapeutics Q4 Revenue $1.0 Mln
Monday, 12 Mar 2018 

March 12 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q4 REVENUE $1.0 MILLION.Q4 REVENUE VIEW $520,000 -- THOMSON REUTERS I/B/E/S.AS OF DECEMBER 31, 2017, HAD AGGREGATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $208.9 MILLION.ACLARIS THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND OPERATIONS INTO H2 2019.  Full Article

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​.ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​.  Full Article

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article